ThinkCyte, a Tokyo, Japan-based company focusing on the development of novel cell therapy, drug discovery and diagnostic platforms, raised $26m in Series B funding.
The round was led by SPARX Group, Sysmex Corporation, Sumitomo Mitsui Trust Investment, SBI Group and Itochu Technology Ventures.
The company intends to use the funds to accelerate:
- the development of its proprietary image-based cell analysis and sorting system for cell therapy,
- clinical diagnostics, and
- drug discovery, business expansion and growth in the global market.
Founded in 2016 and led by Waichiro Katsuda, CEO, ThinkCyte is a biotechnology company which develops innovative life science research, diagnostics, and treatments using integrated multidisciplinary technologies, The company focuses on the research and development of drug discovery, cell therapy, and diagnostic platforms using its proprietary image-based high-throughput cell sorting technology, Ghost Cytometry. In June 2019, the company was selected for J-Startup by the Ministry of Economy, Trade and Industry of Japan.
The company also has offices in San Carlos, CA.